Clinical trials: Acute Myeloid Leukaemia
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
The hypothesis of this study is that lenalidomide can be an effective drug in preventing relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q after allogeneic HSCT.
- Trial name
- LENAMAINT (NCT00720850)
- Testing
- lenalidomide
- Where
- 7 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Technische Universität Dresden
Leukemia, Lymphoma
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
RATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of LMB-2 immunotoxin in treating young patients with relapsed…
- Trial name
- NCT00085150
- Testing
- LMB-2 immunotoxin
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
This phase Ib trial tests the safety, side effects, best dose and effectiveness of tagraxofusp in combination with azacitidine as maintenance therapy in treating patients with CD123 positive acute myeloid leukemia (AML) and…
- Trial name
- NCT06498973
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- City of Hope Medical Center
Cancer, Breast Cancer
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy…
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML)
- Trial name
- NCT02391480
- Testing
- ABBV-075, Venetoclax
- Where
- 10 sites in United States
- Volunteers
- 128 people
- Sponsor
- AbbVie
Acute Myelogenous Leukemia
MRI Assessment of Leukemia Response to Therapy
The purpose of this study is to investigate if a type of magnetic resonance imaging (MRI) scan of the bone marrow before the start of standard chemotherapy can predict complete remission of leukemia patients after the therapy.
- Trial name
- NCT01537159
- Testing
- 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- OHSU Knight Cancer Institute
Relapsed/Refractory Acute Myeloid Leukemia (AML)
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with…
- Trial name
- NCT06049667
- Testing
- NTQ2494 tablet
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Acute Myeloid Leukemia
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
With the aging of society, the incidence of elderly leukemia in China has been increasing year by year. The elderly patients with Acute Leukemia have poor basal state, and there are many important organ diseases such as heart…
- Trial name
- NCT04168138
- Testing
- rhTPO
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huihan Wang
Acute Myeloid Leukemia
Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy
The purpose of this study is to assesses the benefit, safety, and pharmacokinetics (PK) of BST-236 in patients with newly-diagnosed Acute Myeloid Leukemia (AML) who are not eligible for standard induction chemotherapy due to…
- Trial name
- ELPIS (NCT03435848)
- Testing
- BST-236
- Where
- 16 sites in United States, Israel
- Volunteers
- 66 people
- Sponsor
- BioSight Ltd.
Acute Myeloid Leukaemia
MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
Investigator proposed to apply the new dosage form of mitoxantrone hydrochloride liposomes to the clinical treatment of AML, while combining with cytarabine and azacitidine to form the MA+AZA treatment regimen(Mitoxantrone…
- Trial name
- NCT06345365
- Testing
- mitoxantrone liposome, Ara-Cytarabine and azacitidine, Daunorubicin,Ara-Cytarabine, azacitidine
- Where
- 11 sites in China
- Volunteers
- 154 people
- Sponsor
- Zhongnan Hospital
Acute Myeloid Leukemia
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
The standard treatment for patients with acute myeloid leukemia (AML) with an abnormality in the IDH1 gene, who are not eligible for intensive chemotherapy, is a combination of ivosidenib and azacitidine.
- Trial name
- EVOLVE 1 (NCT07075016)
- Testing
- Venetoclax 400
- Where
- 119 sites in Austria, Belgium and 14 more
- Volunteers
- 227 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Aged, Aged, 80 and Over
An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies
Older people with cancer differ from younger patients due to the combined effects of aging, comorbidities and cancer treatments on their health.
- Conditions
- Aged, Aged, 80 and Over, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin
- Trial name
- OCAPI (NCT04052126)
- Testing
- Individualized physical activity program
- Where
- France
- Volunteers
- 43 people
- Sponsor
- Centre Leon Berard
Acute Myeloid Leukemia
Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)
Evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with core-binding factor (CBF) positive acute myeloid leukemia (AML) in the first CR (CR1).
- Trial name
- CBF(+)AML (NCT01146977)
- Testing
- HDAC chemotherapy, Autologous HCT
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Cooperative Study Group A for Hematology
Relapsed/Refractory AML, Relapsed/Refractory ALL
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
In this Phase I study, we will test the safety of the drug plerixafor (MOBOZIL) at different dose levels, used together with other anti-cancer drugs-cytarabine and etoposide.
- Conditions
- Relapsed/Refractory AML, Relapsed/Refractory ALL, Secondary AML/MDS, Acute Leukemia of Ambiguous Lineage
- Trial name
- NCT01319864
- Testing
- Plerixafor Dose Escalation
- Where
- 9 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Seattle Children's Hospital
Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia
Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT
HSCT from an allogeneic donor is the standard therapy for high-risk hematopoietic malignancies and a wide range of severe non-malignant diseases of the blood and immune system.
- Conditions
- Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, in Relapse, High Risk Acute Lymphoblastic Leukemia
- Trial name
- NCT05066958
- Testing
- boost anti-viral immunity after T-cell depleted HSCT
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Leukemia, Myeloid, Acute
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
This is a IIa phase IIa open-label, non-randomized clinical trial of Antroquinonol, capsule, 100 mg (Golden Biotechnology Corporation, Taiwan) in patients with AML.
- Trial name
- NCT03823352
- Testing
- Antroquinonol
- Where
- 2 sites in Russia
- Volunteers
- 12 people
- Sponsor
- Golden Biotechnology Corporation
Acute Myeloid Leukemia
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
The study is to evaluate safety, tolerability and composite CR of IBI188 plus Demethylating Agents in acute myeloid leukemia
- Trial name
- NCT04485052
- Testing
- IBI188, Azacitidine, Decitabine
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Leukemia, Myeloid, Acute
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
This study is a phase I/II study to determine the safety and efficacy of AMD3100 when combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory AML.
- Trial name
- AMD3100+MEC (NCT00512252)
- Testing
- AMD3100, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
Recent studies of conventional chemotherapy for infants with high-risk hematologic malignancies show that the long-term disease-free survival is low.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia
- Trial name
- NCT00145626
- Testing
- Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Jude Children's Research Hospital
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia, Myeloid, Acute
ObServatory Children Acute RElated Therapy Leukemia
Acute Myeloid Leukemias (AML) of the child are a rare disease and its prognosis varies according to the subgroup. Secondary AMLs remain a subgroup of poor prognosis, whose cytogenetic and molecular characteristics and prognostic…
- Trial name
- OSCARE (NCT04450784)
- Testing
- collection of the clinical and biological characteristics of secondary AMLs in children
- Volunteers
- 40 people
- Sponsor
- University Hospital, Bordeaux
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.